L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 562.7 ILS -7.92% Market Closed
Market Cap: 445m ILS

Intrinsic Value

The intrinsic value of one LCTX stock under the Base Case scenario is 411.34 ILS. Compared to the current market price of 562.7 ILS, Lineage Cell Therapeutics Inc is Overvalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LCTX Intrinsic Value
411.34 ILS
Overvaluation 27%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation History
Lineage Cell Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about LCTX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is LCTX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Lineage Cell Therapeutics Inc.

Explain Valuation
Compare LCTX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about LCTX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lineage Cell Therapeutics Inc

Current Assets 43.8m
Cash & Short-Term Investments 42.3m
Receivables 256k
Other Current Assets 1.3m
Non-Current Assets 47m
PP&E 4.1m
Intangibles 42.4m
Other Non-Current Assets 511k
Current Liabilities 10.8m
Accounts Payable 1.5m
Accrued Liabilities 4m
Other Current Liabilities 5.3m
Non-Current Liabilities 31.7m
Long-Term Debt 48k
Other Non-Current Liabilities 31.6m
Efficiency

Free Cash Flow Analysis
Lineage Cell Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Lineage Cell Therapeutics Inc

Revenue
10.9m USD
Cost of Revenue
-267k USD
Gross Profit
10.6m USD
Operating Expenses
-31m USD
Operating Income
-20.4m USD
Other Expenses
-20.5m USD
Net Income
-40.9m USD
Fundamental Scores

LCTX Profitability Score
Profitability Due Diligence

Lineage Cell Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
Operating Margin is Increasing
24/100
Profitability
Score

Lineage Cell Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

LCTX Solvency Score
Solvency Due Diligence

Lineage Cell Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
51/100
Solvency
Score

Lineage Cell Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 372.9 ILS with a low forecast of 652.52 ILS and a high forecast of 3 052.65 ILS.

Lowest
Price Target
652.52 ILS
16% Upside
Average
Price Target
1 372.9 ILS
144% Upside
Highest
Price Target
3 052.65 ILS
443% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Lineage Cell Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for LCTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

LCTX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one LCTX stock?

The intrinsic value of one LCTX stock under the Base Case scenario is 411.34 ILS.

Is LCTX stock undervalued or overvalued?

Compared to the current market price of 562.7 ILS, Lineage Cell Therapeutics Inc is Overvalued by 27%.

Back to Top